Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist

Add time:08/09/2019    Source:sciencedirect.com

Orexins play an important role in sleep/wake regulation, and orexin receptor antagonists are a focus of novel therapy for the treatment of insomnia. We identified 27e (TASP0428980) as a potent dual orexin receptor antagonist through the systematic modification of our original designed lead A. We demonstrated the potent sleep-promoting effects of 27e at ip dose of 3 mg/kg in a rat polysomnogram study. 27e exhibited relatively short half-life profiles in rats and dogs. Furthermore, accumulating evidence regarding ADME profiles indicates that the predicted human half-life of 27e should be 1.2–1.4 h. These data indicated that 27e has a short-acting hypnotic property, suggesting that 27e might be useful for treating primary insomnia while exhibiting a low risk of next-day residual somnolence. Thus, 27e and its related compounds should be further evaluated to enable advancement to clinical trials.

We also recommend Trading Suppliers and Manufacturers of ETHYL 2-BROMO-(2-PYRIDINYL)ACETATE (cas 123761-15-9). Pls Click Website Link as below: cas 123761-15-9 suppliers

Prev:triwaglerin (cas 123759-96-6): a potent platelet aggregation inducer purified from Trimeresurus wagleri snake venom
Next:Synthesis of new N-substituted 3,4,5-trihydroxypiperidin-2-ones from d)